Evidence map›Paper›PMID 28660216›Full record

ArticleJournal of immunology research2017

Chitinase-3-Like Protein 1 (YKL-40) Reflects the Severity of Symptoms in Atopic Dermatitis.

Joanna Salomon, Łukasz Matusiak, Danuta Nowicka-Suszko, Jacek C Szepietowski

Abstract read
In one paragraph

Article in Journal of immunology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Chitinase-3-like 1 regulates TFrontiers in immunology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Joanna SalomonDepartment of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland.
Łukasz MatusiakDepartment of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland.
Danuta Nowicka-SuszkoDepartment of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland.
Jacek C SzepietowskiDepartment of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland.ORCID 0000-0003-0766-6342

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chitinase-3-like protein 1 (YKL-40) is suggested to be associated with type 2 T helper response and atopy. The aim of the study was the evaluation of serum YKL-40 level in atopic dermatitis. The study was performed on 59 patients: 27 males and 32 females, aged from 18 to 64 years. The severity of the disease was assessed by the SCORAD and objective SCORAD indexes. The severity of pruritus was measured by the visual analogue scale. Blood samples were taken to examine serum level of YKL-40, total IgE level, C-reactive protein level, white blood cell count, and neutrophil count. YKL-40 serum levels were significantly higher in patients with atopic dermatitis compared to the controls. There was a positive correlation between YKL-40 concentration and SCORAD, objective SCORAD, and pruritus. This study has shown that YKL-40 serum level is increased in patients with atopic dermatitis and reflects the severity of symptoms.

Indexed as

AdolescentAdultChitinase-3-Like Protein 1C-Reactive ProteinDermatitis, AtopicFemaleHumansImmunoglobulin ELeukocyte CountMaleMiddle AgedNeutrophilsProspective StudiesPruritusSeverity of Illness IndexYoung AdultCHI3L1 protein, humanChitinase-3-Like Protein 1C-Reactive ProteinImmunoglobulin E

Identifiers

PMID28660216
PMCPMC5474268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.